MeVis Medical Solutions AG (FRA:M3V)

FRA:M3V Cash Flow Statement

Financials in millions EUR. Fiscal year is October - September.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	4.56	4.92	7.79	4.55	5.7
Depreciation & Amortization	0.13	0.1	0.09	0.13	0.17
Other Operating Activities	-1.07	-0.46	-1.62	-0.25	-0.35
Change in Accounts Receivable	0.57	1.58	-1.91	3.9	-2.62
Change in Accounts Payable	-0.13	0.05	-0.27	0.34	-0.23
Change in Other Net Operating Assets	-0.91	-0.32	0.77	0.46	0.21
Operating Cash Flow	3.15	5.85	4.86	9.13	2.89
Operating Cash Flow Growth	-46.25%	20.52%	-46.80%	215.97%	-55.84%
Capital Expenditures	-0.3	-0.08	-0.13	-0.05	-0.1
Investment in Securities	0.01	-	-	-	-
Other Investing Activities	1.2	1.07	0.19	0.16	0.29
Investing Cash Flow	0.91	0.99	0.06	0.11	0.19
Other Financing Activities	-4.92	-7.79	-4.55	-5.7	-1.57
Financing Cash Flow	-4.92	-7.79	-4.55	-5.7	-1.57
Foreign Exchange Rate Adjustments	-0.35	-0.63	1.33	0.13	-0.15
Net Cash Flow	-1.22	-1.58	1.7	3.67	1.35
Free Cash Flow	2.84	5.77	4.72	9.08	2.79
Free Cash Flow Growth	-50.74%	22.23%	-47.97%	225.78%	-56.05%
Free Cash Flow Margin	16.76%	33.30%	25.18%	56.00%	16.27%
Free Cash Flow Per Share	1.56	3.17	2.60	4.99	1.53
Cash Interest Paid	-	-	-	0	-
Cash Income Tax Paid	0.29	0.12	0.17	0	0.35
Levered Free Cash Flow	2.43	4.28	2.75	9.07	-2.66
Unlevered Free Cash Flow	2.43	4.28	2.75	9.07	-2.66
Change in Net Working Capital	-0.11	-1.22	1.25	-5.86	6.2

Source: S&P Global Market Intelligence. Standard template. Financial Sources.